Announced positive interim data from PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, enabling advancement into Phase 3 expected by Q1 2025.

Interim 24-week landmark analysis from PRISM Phase 2 Population Extension cohort evaluating 4D-150 in broader wet AMD population expected to be presented at ASRS in July 2024.

Interim clinical data from Phase 1/2 AEROW clinical trial expected to be presented at the European Cystic Fibrosis Society Conference in June 2024.

Completed upsized public follow-on offering with total gross proceeds of $337 million, resulting in $589 million in cash and equivalents as of March 31, 2024.